Peps
What is Gonadorelin?
Gonadorelin is gonadotropin-releasing hormone. A clinical series studied pulsatile administration in women with hypothalamic amenorrhea, a specific reproductive-hormone disorder.
Biological role or research focus
Hypothalamic amenorrhea and fertility physiology.
These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
Role reference: Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. · 1990 ↗
Names you may encounter
GnRH-I
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Gonadotropin-releasing hormone decapeptide
- Research focus
- Hypothalamic amenorrhea and fertility physiology
- Featured evidence
- Human clinical series
- Source check
- October 4, 2026
Molecular structure
How Gonadorelin works
The timing of GnRH signaling matters. Pulsatile replacement and sustained stimulation by a long-acting analogue can produce different endocrine effects; the names cannot be treated as interchangeable interventions.
Clinical context & research status
The selected report concerns specialist fertility treatment in hypothalamic amenorrhea. It does not establish general testosterone enhancement or fertility improvement across all causes.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human clinical series · 1990
Multicenter pulsatile GnRH clinical series
What outcomes were reported with pulsatile GnRH in hypothalamic amenorrhea?
- Population / model
- 109 women with primary or secondary hypothalamic amenorrhea.
- Study design
- Multicenter clinical series of pulsatile GnRH treatment; the abstract does not describe a randomized placebo-controlled comparison.
- Main finding
- Reported ovulation rates were 91% in primary and 96% in secondary amenorrhea. Multiple pregnancies occurred in 12%; intravenous-line complications averaged 7%.
- Limits & context
- These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Premenstrual syndrome. ↗
BMJ clinical evidence · 2007 May 1 · Journal Article, Systematic Review
Breast pain. ↗
BMJ clinical evidence · 2011 Jan 17 · Journal Article, Systematic Review
Read available full text ↗
Endometriosis. ↗
BMJ clinical evidence · 2007 Mar 1 · Journal Article, Systematic Review
Read available full text ↗
Endometriosis. ↗
BMJ clinical evidence · 2010 Aug 13 · Journal Article, Systematic Review
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Multiple pregnancy and intravenous-line complications were reported. The study cannot establish safety or benefit for unrelated reproductive disorders.
Identity, route, and evidence limits
These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
1 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Doğal Testosteronu Uçuran Peptid: Gonadorelin Nedir? ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is pulsatile gonadorelin equivalent to a long-acting GnRH agonist?
- What population, comparator, and route were actually studied?
- These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is pulsatile gonadorelin equivalent to a long-acting GnRH agonist?
No. Pulsatile signaling can stimulate reproductive hormone release, whereas sustained agonist exposure may suppress the pathway. Clinical purpose and timing matter.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.